Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Newly detected impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2 DM) are common in patients with acute coronary syndrome (ACS; i.e. unstable angina/myocardial infarction) and related to disturbed beta‐cell function. The aim of this study is to test the hypothesis that treatment with a dipeptidyl peptidase‐4 inhibitor initiated soon after a coronary event improves beta‐cell function. Methods: Acute coronary syndrome ACS patients with IGT or T2 DM (n = 71), screened by oral glucose tolerance test (OGTT) 4–23 days (median 6 days) after hospital admission, were randomly assigned to sitagliptin 100 mg (n = 34) or placebo (n = 37) and treated for a duration of 12 weeks. All patients received lifestyle advice but no glucose‐lowering agents other than the study drug. The study end‐point was beta‐cell function assessed using the insulinogenic index (IGI = ΔInsulin 30/ΔGlucose 30), derived from an OGTT, and acute insulin response to glucose (AIR g) assessed by a frequently sampled intravenous glucose tolerance test. Results: The IGI and AIR g did not differ at baseline between the sitagliptin and placebo groups (69.9 vs. 66.4 pmol mmol−1 and 1394 vs. 1106 pmol L−1 min−1 respectively). After 12 weeks, the IGI was 85.0 in the sitagliptin and 58.1 pmol/mmol in the placebo group (P = 0.013) and AIR g was 1909 and 1043 pmol L−1 min−1 (P < 0.0001) in the sitagliptin and placebo groups respectively. Fasting glucose at baseline was 6.1 mmol L−1 in sitagliptin‐treated patients and 6.0 mmol L−1 in those who received placebo compared with 5.8 and 5.9 mmol L−1 respectively, after 12 weeks of treatment. Post load glucose metabolism improved in significantly more sitagliptin‐treated patients compared with the placebo group (P = 0.003). Sitagliptin was well tolerated. Conclusion: Sitagliptin improved beta‐cell function and glucose perturbations in patients with ACS and newly diagnosed glucose disturbances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112
Self-citationSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
BARTNIK, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.07.027 · Cited by 617
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188
Pathophysiology of prediabetes
Ferrannini, E., Gastaldelli, A., & Iozzo, P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.005 · Cited by 177
Cited by
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Kleinherenbrink, W., Osei, E., den Hertog, H. M., & Zandbergen, A. A. M. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.07.001 · Cited by 31
Kaku, K., Kadowaki, T., Terauchi, Y., Okamoto, T., Sato, A., Okuyama, K., Arjona Ferreira, J. C., & Goldstein, B. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12507 · Cited by 22
Metadata
- Authors
- Hage, C., Brismar, K., Efendic, S., Lundman, P., Rydén, L., & Mellbin, L.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2013-02-14
- Volume
- 273
- Issue
- 4
- Pages
- 410-421
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1964255176
- Cited by
- 22
- References
- 10
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study. https://app.cochat.ai/papers/10.1111/joim.12032
- The paper
- Hage, C., Brismar, K., Efendic, S., Lundman, P., Rydén, L., & Mellbin, L. (2013). Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study. Journal of Internal Medicine. https://doi.org/10.1111/joim.12032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.